Hongene Biotechnology Signs License Agreement with Marina Biotech

Hongene Biotechnology, a China manufacturer of nucleosides and nucleotides in China, signed a strategic license agreement with Marina Biotech of the US, a leading nucleic acid-based drug discovery and development company focused on rare diseases. Hongene will have the exclusive right to develop, supply and commercialize certain oligonucleotide constructs using Marina’s Conformationally Restricted Nucleotide (CRN) Chemistry. The agreement, in turn, calls for Hongene to pay Marina Biotech royalties from the sale of CRN-based oligonucleotide reagents and to provide a stable supply of CRN-based oligonucleotides to Marina, which will be used for Marina and its partners’ drug development and commercialization. More details.... Stock Symbol: (OTCQB: MRNA) Share this with colleagues: // //